-1 	|BT| (S (PP (IN In) (NP (NN silico) (NN analysis))) (VP (VBD used) (SBAR (S (NP (NN probe) (NN association) (NN gene) (NN expression) (NN signature) (NN RB) (NN loss) (JJ chromosomal) (NN instability) (NN ability) (NN gene)) (VP (VBD up-regulated) (SBAR (S (NP (NN RB) (NN loss)) (VP (VBP predict) (NP (NN survival) (JJ human) (NN HCC) (NN patient)))))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 96:I03.784 104:C04.557.470.200.025.255 142:I01.880.604 150:Z01.542.248.960 383:C23.550.210.110 384:G02.111.087.847.750 385:F02.784.629.131 386:F02.463.425.069 387:L01.224.160|ES| 9:1 19:1 32:1 36:1 115:1 120:1 244:1 274:1 441:1 476:1 661:1 1002:1 1209:1 1230:1 1296:1 1297:1 1298:1 1299:1 1300:1 1301:1 1302:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD found) (S (S (NP (NN EREG) (JJ overexpressed) (NNS NSCLCs)) (VP (VBG harboring) (NP (NNP KRAS)))) (, ,) (NP (NNP BRAF) (NN EGFR) (NN mutation)) (VP (VBN compared) (NP (NNS NSCLCs) (JJ wild-type) (NN KRAS/BRAF/EGFR)))))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 388:G05.360.340.024.340.375.500.791.550|ES| 2:1 8:1 19:1 25:1 34:1 37:1 50:1 131:1 175:1 187:1 244:1 958:1 1137:1 1303:1 1304:1 1305:1 1306:1
-1 	|BT| (UCP (PP (IN In) (NP (JJ present) (NN study) (JJ novel) (JJ metastasis-related) (NN gene))) (, ,) (NP (NP (NP (JJ eukaryotic) (NN initiation) (NN factor) (NN 5A2)) (PRN (-LRB- -LRB-) (NP (NN EIF5A2)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN characterized) (NN role) (NN HCC) (NN metastasis)) (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 259:D12.776.395.240.150.500 389:D12.776.835.725.868|ES| 2:1 9:1 10:1 14:1 19:1 31:1 131:1 161:1 162:1 185:1 244:1 435:1 441:1 637:1 806:1 891:1 985:1 1307:1 1308:1 1309:1 1310:1 1311:1
-1 	|BT| (NP (NP (NP (VBN Increased) (NN loss) (NN chromosome) (NN 9p21) (NN p16) (NN inactivation)) (NP (JJ primary) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN smoker)))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 289:A11.284.187|ES| 18:1 19:1 32:1 94:1 328:1 344:1 694:1 1005:1 1212:1 1312:1 1313:1 1314:1 1315:1
-1 	|BT| (S (NP (NN ING5)) (VP (VP (VBZ suppresses) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN migration) (NN invasion)))) (, ,) (VP (VBZ induces) (NP (JJ autophagy) (NN differentiation) (JJ gastric) (NN cancer) (NN cell))) (: :) (NP (JJ good) (NN marker) (NN carcinogenesis) (JJ subsequent) (NN progression)))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 39:G04.299.139.160 74:G04.299.151 158:D23.101 390:G04.299.139.399|ES| 2:1 18:1 19:1 48:1 86:1 89:1 94:1 104:1 207:1 214:1 215:1 299:1 514:1 534:1 620:1 686:1 1316:1 1317:1 1318:1 1319:1
-1 	|BT| (NP (NP (JJ Irrespective) (NN protein) (NN overexpression)) (, ,) (S (NP (NN HER-2)) (: /) (NP (NP (NN neu) (NN gene) (NN amplification) (JJ rare) (NN lung) (NN cancer) (NN study) (NN prevalence) (JJ clinicopathological) (NN implication) (JJ early) (NN stage) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NCSLC)) (-RRB- -RRB-))) (NP (NP (JJ neuroendocrine) (NN tumour)) (PRN (-LRB- -LRB-) (NP (NN NET)) (-RRB- -RRB-))) (VP (NN lung) (S (VP (VBG lacking)))))) |ET| |BS|7:D12.776 63:G05.360.340.024.340.375.500.791.295.305 110:C04.588.894.797.520.109.220.249 237:C04.588.894.797.520 391:E05.318.760.500.875 392:G05.355.315.250 393:A06.688|ES| 2:1 4:1 9:1 10:1 14:1 18:1 19:1 85:1 94:1 131:1 152:1 179:1 328:1 376:1 694:1 921:1 1011:1 1128:1 1129:1 1320:1 1321:1 1322:1 1323:1 1324:1 1325:1 1326:1
-1 	|BT| (S (NP (PRP It)) (ADJP (ADJP (RB likely) (JJ major)) (SBAR (S (NP (NN genotype) (JJ gastric) (NN carcinoma)) (VP (VBD placed) (NP (JJS least) (CD 4) (NN microsatellite) (NN category)) (, ,) (S (ADVP (RB thus)) (VP (VBG allowing) (NP (NP (NN construction) (JJ comprehensive) (JJ genetic) (NN classification)) (JJ useful) (NN prediction) (JJ diverse) (JJ clinical) (NN course))))))))) |ET| |BS|70:A03.556.875.875 265:C04.557.470.200 394:G02.111.570.080.708.800.500 395:L01.100 396:G05.380|ES| 2:1 19:1 84:1 86:1 304:1 319:1 462:1 864:1 1036:1 1327:1 1328:1 1329:1 1330:1 1331:1 1332:1 1333:1 1334:1 1335:1 1336:1 1337:1 1338:1 1339:1 1340:1 1341:1
-1 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN expression)) (VP (MD might) (VP (VP (VBN employed) (S (NP (JJ good) (NN marker) (JJ gastric) (NN carcinogenesis) (JJ subsequent) (NN progression)) (VP (VBG inhibiting) (NP (NN proliferation))))) (, ,) (NP (NP (NN growth)) (, ,) (NP (NN migration)) (, ,) (NP (NN invasion) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 45:G07.700.320.249 70:A03.556.875.875 113:C04.697.650 122:C14.280.383 158:D23.101|ES| 2:1 19:1 48:1 86:1 102:1 115:1 207:1 299:1 514:1 534:1 620:1 798:1 806:1 880:1 925:1 1316:1 1318:1 1319:1 1327:1 1342:1
-1 	|BT| (S (NP (JJ Knock-down) (NN Prmt1) (JJ insufficient) (JJ reverse) (JJ active) (NN chromatin) (NN status)) (VP (VBN hypomethylated) (NP (NN Hox) (NN locus)) (, ,) (S (VP (VBG suggesting) (S (NP (JJ Prmt1-mediated) (NN histone) (NN arginine) (NN methylation)) (VP (ADVP (RB partially)) (NP (VBN involved) (NP (NN maintenance) (NN Hox) (NN expression) (JJ leukaemic) (NN cell))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 188:N02.628 351:A17.360 397:A11.284.430.106.279.345.190.160.180 398:D12.125.068.050 399:D12.776.660.470|ES| 2:1 19:1 81:1 94:1 115:1 197:1 377:1 416:1 503:1 774:1 939:1 1009:1 1063:1 1203:1 1343:1 1344:1 1345:1 1346:1 1347:1 1348:1 1349:1 1350:1 1351:1
-1 	|BT| (S (NP (JJ Knock-down) (NN TnC) (NN gene)) (VP (VBD increased) (NP (NN susceptibility) (JJ DSS-induced) (NN colitis)) (, ,) (S (VP (VBN compared) (S (NP (NP (NN TnC)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NNS littermates))))))) |ET| |BS|53:C06.405.205.265 400:E05.393.335.500 401:C23.550.291.687|ES| 2:1 9:1 10:1 14:1 19:1 47:1 50:1 51:1 143:1 1343:1 1352:1 1353:1 1354:1 1355:1
-1 	|BT| (NP (NP (S (NP (JJ K-ras) (NN gene) (NN mutation)) (VP (VBZ enhances) (NP (NN motility) (VBN immortalized) (NN airway) (NN cell) (NN lung) (NN adenocarcinoma) (NN cell)) (PP (IN via) (NP (NN Akt) (NN activation)))) (: :)) (NP (JJ possible) (NN contribution) (JJ non-invasive) (NN expansion) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 41:A11 378:D08.811.913.696.620.682.700.755|ES| 9:1 19:1 34:1 94:1 104:1 225:1 255:1 328:1 596:1 1121:1 1177:1 1289:1 1356:1 1357:1 1358:1 1359:1 1360:1 1361:1 1362:1
-1 	|BT| (S (NP (NNP KRAS) (NN gene) (NN mutation)) (VP (VBN linked) (NP (NP (JJ poor) (NN prognosis) (NN resistance)) (JJ therapeutic) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|18:G05.365.590 52:E02 110:C04.588.894.797.520.109.220.249 159:I01.880.735.634 163:E01.789|ES| 9:1 10:1 14:1 18:1 19:1 34:1 94:1 328:1 329:1 541:1 544:1 545:1 694:1 1094:1 1305:1 1363:1
-1 	|BT| (NP (NP (NP (JJ K-ras) (NN gene) (JJ mutational) (NN analysis)) (NN support) (JJ monoclonal) (NN origin) (JJ biphasic) (JJ pleomorphic) (NN carcinoma) (NN lung))) |ET| |BS|18:G05.365.590 149:G05.360.340.024.340.364.875.890 182:A04.411 265:C04.557.470.200|ES| 9:1 19:1 304:1 328:1 661:1 1121:1 1244:1 1364:1 1365:1 1366:1 1367:1 1368:1
-1 	|BT| (NP (NP (NP (NP (NNP KRAS) (NN mutation) (CD one) (JJ common) (NN driver) (NN mutation) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (SBAR (S (NP (NN finding) (JJ druggable) (NN target) (NN molecule)) (VP (VBP inhibit) (NP (JJ oncogenic) (NNP KRAS) (NN signaling) (JJ significant) (NN challenge) (NN NSCLC) (NN therapy))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 69:G02.111.087.800 110:C04.588.894.797.520.109.220.249 122:C14.280.383 275:C23.888 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 10:1 14:1 18:1 19:1 34:1 130:1 135:1 160:1 180:1 195:1 327:1 328:1 329:1 655:1 927:1 953:1 954:1 1010:1 1305:1 1369:1 1370:1 1371:1
-1 	|BT| (S (NP (NNP LOH) (NNP FHIT) (NN locus)) (ADVP (RB frequently)) (VP (VBN found) (PP (IN among) (NP (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium) (NN patient) (NN IPF))) (PRN (-LRB- -LSB-) (NP (NP (CD 62) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-))) (NP (CD 119) (JJ informative) (NN lesion))) (-RRB- -RSB-)))) |ET| |BS|48:C23.550.589 50:M01.643 62:A10.272 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 10:1 14:1 19:1 37:1 120:1 173:1 369:1 377:1 698:1 946:1 1004:1 1122:1 1131:1 1222:1 1223:1 1372:1 1373:1 1374:1 1375:1 1376:1 1377:1 1378:1
-1 	|BT| (NP (NP (JJ Mammary) (NN analogue) (JJ secretory) (NN carcinoma) (JJ salivary) (NN gland) (JJ high-grade) (NN transformation)) (: :) (NP (NP (NN report) (ADJP (CD 3) (NN case)) (NN ETV6-NTRK3) (NN gene) (NN fusion) (NN analysis) (NN TP53)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NN EGFR)) (, ,) (NP (NN CCND1) (NN gene)))) |ET| |BS|23:D12.776.091.249 359:G05.355.760.385 402:G05.360.340.024.340.375.500.791.148 403:C04.557.470.200.588 404:A03.556.500.760 405:V03.100 406:V03.100|ES| 2:1 9:1 19:1 60:1 104:1 187:1 304:1 417:1 643:1 661:1 862:1 934:1 936:1 1018:1 1025:1 1379:1 1380:1 1381:1 1382:1 1383:1 1384:1 1385:1
-1 	|BT| (NP (NP (NP (JJ Mammary) (NN tumour)) (NP (VBN observed) (NN EphB4) (JJ transgenic) (NN animal))) (: ;) (NP (ADVP (RB however)) (, ,) (NP (NP (JJ double) (JJ transgenic) (NN animal) (VBG expressing) (NN EphB4) (NN neuT) (NN gene)) (, ,) (NP (NN tumour) (NN appearance)) (S (S (ADVP (RB significantly)) (VP (VBD accelerated))) (, ,) (NP (NP (NN contrast) (JJ neuT-only) (NN animal)) (, ,) (NP (NN metastasis)) (NP (VBD observed) (NN lung))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 19:B01.050 113:C04.697.650 182:A04.411 352:B01.050.050.136 407:E01.370.225.812.735.550 408:C04.588.531|ES| 2:1 9:1 19:1 46:1 124:1 217:1 261:1 285:1 328:1 806:1 810:1 1011:1 1379:1 1386:1 1387:1 1388:1 1389:1 1390:1 1391:1 1392:1 1393:1
-1 	|BT| (S (NP (JJ Maternal) (NN folate) (NN level) (NN polymorphism) (JJ folate-related) (NN gene)) (VP (VBN known) (NP (NP (NN risk) (NN factor) (JJ neural) (NN tube) (NN defect)) (PRN (-LRB- -LRB-) (NP (NNS NTDs)) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 224:D03.438.733.631.400 307:G05.365.795 409:E05.318.740.600.800.725 410:F01.829.263.500.320.200 411:C10.500.680|ES| 9:1 10:1 14:1 19:1 171:1 185:1 249:1 556:1 588:1 778:1 1060:1 1394:1 1395:1 1396:1 1397:1 1398:1
-1 	|BT| (S (NP (NNS METHODS) (: :)) (NP (NP (JJ Aberrant) (NN methylation) (NN status) (NN p16) (NN promoter) (NN region)) (, ,) (NP (NN expression) (NN product)) (, ,) (NP (NP (NN loss) (NN heterozygosity)) (PRN (-LRB- -LRB-) (NP (NN LOH)) (-RRB- -RRB-))) (NP (NN 9p21))) (VP (VBD examined) (NP (NP (NP (ADJP (RB surgically) (JJ resected)) (NN lung) (NN specimen) (CD 57) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 28) (JJ male) (CD 29) (NN female)) (-RRB- -RRB-))) (S (NP (JJ peripheral-type) (NN lung) (NN adenocarcinoma)) (VP (VBG measuring) (NP (ADVP (JJR <) (: /)) (NP (JJ =) (CD 2) (NN cm) (NN diameter)))))))) |ET| |BS|36:G02.111.087.029.538 50:M01.643 115:E04 168:E05.581 182:A04.411 196:G02.111.570.080.689.675 203:G05.360.340.024.340.375.249.375 228:E05.978 290:G05.365.590.029.530|ES| 2:1 10:1 14:1 19:1 32:1 80:1 81:1 83:1 104:1 115:1 120:1 148:1 255:1 312:1 324:1 326:1 328:1 416:1 528:1 565:1 667:1 675:1 1004:1 1154:1 1312:1 1313:1 1399:1 1400:1 1401:1 1402:1 1403:1 1404:1 1405:1 1406:1 1407:1 1408:1 1409:1
-1 	|BT| (NP (NP (NN Methylation) (NN TFPI2) (NN stool) (NN DNA)) (: :) (NP (JJ potential) (JJ novel) (NN biomarker) (NN detection) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 36:G02.111.087.029.538 158:D23.101 198:D13.444.308 259:D12.776.395.240.150.500 355:A12.459|ES| 17:1 18:1 19:1 104:1 572:1 666:1 827:1 885:1 891:1 1023:1 1184:1 1185:1
-1 	|BT| (S (NP (NNS Mutations) (NN EGFR) (NN gene)) (VP (VBD detected) (NP (NP (JJ pulmonary) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS ADCs)) (-RRB- -RRB-))))) |ET| |BS|18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 9:1 10:1 14:1 19:1 187:1 255:1 948:1 1007:1 1410:1 1411:1
-1 	|BT| (NP (NP (NNP New) (NN aspect) (JJ clinicopathologic) (NN oncogene) (NN study)) (NP (CD 23) (JJ pulmonary) (JJ lymphoepithelioma-like) (NN carcinoma))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 265:C04.557.470.200|ES| 19:1 24:1 131:1 304:1 948:1 1412:1 1413:1 1414:1 1415:1 1416:1
-1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (VP (TO To) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NP (JJ brain-targeted) (NN gene) (NN therapy) (JJ recombinant) (JJ adeno-associated) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN rAAV5)) (-RRB- -RRB-))) (: -) (NP (NN IDUA) (NN vector) (NN MPS-I) (JJ transgenic) (NN mouse) (NN model))) (VP (MD would) (VP (VB reverse) (NP (JJ pathological) (NN hallmark))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 99:B01.050.050.136.500 367:A08.186.211 412:C16.320.565.202.715.640 413:B04.280.580.650.170 414:B04.280.580.650.170 415:F01.658.500 416:G05.360.337 417:H02.403.650|ES| 9:1 10:1 14:1 19:1 52:1 72:1 104:1 130:1 221:1 285:1 362:1 828:1 866:1 939:1 1417:1 1418:1 1419:1 1420:1 1421:1 1422:1 1423:1 1424:1 1425:1 1426:1 1427:1
-1 	|BT| (NP (NP (NP (JJ Odd-skipped) (JJ related) (CD 1) (JJ novel) (NN tumour) (NN suppressor) (NN gene)) (JJ potential) (JJ prognostic) (NN biomarker) (JJ gastric) (NN cancer))) |ET| |BS|158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 18:1 19:1 86:1 98:1 419:1 700:1 827:1 884:1 885:1 891:1 1011:1 1428:1
-1 	|BT| (S (PP (IN Of) (NP (JJ acidophilic) (NN lesion))) (PRN (, ,) (NP (NP (NP (NN majority) (NN focus)) (PRN (-LRB- -LRB-) (NP (NP (CD 28/32)) (, ,) (NP (CD 88) (NN %))) (-RRB- -RRB-))) (NN adenoma) (-LRB- -LRB-) (CD 47/50) (, ,) (NP (CD 94) (NN %))) (-RRB- -RRB-)) (VP (VBD expressed) (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (VP (VBN increased) (SBAR (S (NP (NN bcl-2)) (VP (VBN observed) (NP (NP (ADJP (CD 12.5) (NN %)) (JJ acidophilic) (JJ preneoplastic) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/32)) (-RRB- -RRB-))) (NP (NP (ADJP (CD 14) (NN %)) (JJ acidophilic) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 7/50)) (-RRB- -RRB-))))))))))) |ET| |BS|17:C04.557.470.035 54:G05.360.340.024.340.375.500.791.150 418:D12.644.360.075.718.937 419:C04.557.465.625.650.025|ES| 2:1 6:1 10:1 14:1 19:1 42:1 47:1 151:1 198:1 261:1 369:1 372:1 1131:1 1194:1 1429:1 1430:1 1431:1 1432:1 1433:1 1434:1 1435:1 1436:1 1437:1 1438:1 1439:1 1440:1 1441:1
-1 	|BT| (SINV (PP (IN Of) (NP (JJ small-cell) (JJ heterogeneous) (JJ basophilic) (NN lesion))) (, ,) (CD 86) (VP (NN %) (VP (NN focus) (SBAR (S (-LRB- -LRB-) (S (S (NP (NP (QP (CD 31/36) (-RRB- -RRB-) (CD 85) (NN %)) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 35/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (VBN increased) (NN bcl-2) (NN protein) (NN level)) (PP (VBN compared) (S (VP (VBG surrounding) (NP (JJ normal) (NNS hepatocytes)))))))) (, ,) (IN whereas) (S (NP (NP (NP (ADJP (CD 12.5) (NN %)) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/36)) (-RRB- -RRB-))) (ADJP (CD 12) (NN %)) (NN adenoma) (PRN (-LRB- -LRB-) (NP (CD 5/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (NN level)))))))))) |ET| |BS|7:D12.776 17:C04.557.470.035 41:A11 54:G05.360.340.024.340.375.500.791.150 175:J01.897.280.500.269 262:A11.436.348 418:D12.644.360.075.718.937 420:A11.118.637.415.120 421:G05.365.331 422:N01|ES| 2:1 4:1 10:1 14:1 19:1 42:1 47:1 50:1 118:1 151:1 249:1 369:1 372:1 609:1 894:1 1120:1 1131:1 1429:1 1431:1 1435:1 1436:1 1437:1 1442:1 1443:1 1444:1 1445:1 1446:1 1447:1 1448:1 1449:1 1450:1 1451:1
-1 	|BT| (S (ADVP (NP (CD One) (NN year)) (RB later)) (, ,) (NP (JJ intra-abdominal) (JJ metastatic) (NN tumor)) (VP (VBD detected) (ADJP (JJ resected)))) |ET| |BS|8:C04 9:G05.360.340.024.340.375.500 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 158:D23.101 198:D13.444.308 303:C04.557.450.795 372:G05.360.340.024.340.137.232 423:A01.923.047.025 424:L01.143.506.423.557 425:G01.358.500.505.650 426:E01.370.350.515 427:C04.588.033 428:D27.720.233|ES| 2:1 7:1 9:1 19:1 68:1 118:1 127:1 272:1 337:1 344:1 534:1 654:1 666:1 806:1 833:1 965:1 1007:1 1021:1 1055:1 1250:1 1255:1 1327:1 1400:1 1452:1 1453:1 1454:1 1455:1 1456:1 1457:1 1458:1 1459:1 1460:1 1461:1 1462:1 1463:1 1464:1 1465:1 1466:1 1467:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB firmly)) (VP (VBP establish) (NP (JJ unique) (JJ oncogenic) (NN capability) (NN DNp73) (NN drive)) (ADVP (FW hepatocarcinogenesis) (FW vivo)) (, ,) (S (VP (VBG supporting) (NP (NN significance) (NN marker) (NN disease) (NN severity) (NN patient) (NN target) (NN cancer) (NN prevention)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 66:F01.658.293 158:D23.101 279:D27.888.569.100 288:C23.550.288|ES| 2:1 18:1 19:1 120:1 160:1 181:1 220:1 378:1 534:1 557:1 658:1 793:1 900:1 953:1 998:1 1468:1 1469:1 1470:1 1471:1 1472:1 1473:1 1474:1
-1 	|BT| (NP (NP (PRP$ Our) (S (VP (NN finding) (VP (VB identify) (NP (NN EphA1) (JJ potential) (JJ prognostic) (NN marker) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 158:D23.101|ES| 19:1 245:1 534:1 658:1 827:1 832:1 884:1 927:1 994:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (JJ allelic) (NN loss) (NN FHIT) (NN gene)) (VP (MD may) (NP (VBN involved) (NN carcinogenesis) (JJ peripheral) (NN lung) (NN patient) (NN IPF))))))) |ET| |BS|6:G05.360.340.024.340 33:C04.697.098 50:M01.643 182:A04.411 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765|ES| 9:1 19:1 32:1 120:1 207:1 328:1 491:1 658:1 774:1 796:1 927:1 946:1 1122:1 1475:1 1476:1
-1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (NN KLLN)) (VP (MD might) (VP (VBN used) (NP (JJ potential) (JJ prognostic) (NN marker) (JJ novel) (NN therapy) (NN target) (NN breast) (NN carcinoma)))))))) |ET| |BS|52:E02 158:D23.101 259:D12.776.395.240.150.500 429:N04.761.559.590.900 430:E05.581.249|ES| 19:1 23:1 130:1 160:1 304:1 476:1 534:1 658:1 796:1 798:1 827:1 884:1 891:1 1477:1 1478:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (NP (S (NP (NN miR-9) (NN miR-197)) (VP (ADVP (RB specifically)) (VBP downregulate) (NP (NN MTHFD1L) (NN level) (NN HEK293) (NN MCF-7) (NN cell) (NN SNPrs7646)) (ADVP (RB significantly)) (VP (VBP affect) (NP (NP (NN miR-197) (NN binding) (NN affinity) (NN MTHFD1L) (CD 3)) ('' ') (NN UTR)) (, ,) (S (VP (VBG causing) (NP (NP (JJ efficient) (JJ posttranscriptional) (NN gene) (NN repression) (NN presence) (NN allele)) (VP (VBN associated)))))))) (NP (VBD increased) (NN risk) (NNS NTDs))))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 77:G05.360.340.024.340.030 208:F01.393.821 252:F02.784.692.351 411:C10.500.680 431:D13.444.735.544.875 432:A11.251.210.190.630 433:F01.470.047|ES| 2:1 9:1 19:1 47:1 94:1 101:1 124:1 169:1 171:1 230:1 249:1 346:1 508:1 658:1 706:1 862:1 1279:1 1398:1 1479:1 1480:1 1481:1 1482:1 1483:1 1484:1 1485:1 1486:1 1487:1 1488:1 1489:1 1490:1 1491:1 1492:1 1493:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (S (NP (NN offer) (JJ preclinical) (NN rationale)) (VP (VBG warranting) (NP (NP (JJ clinical) (NN investigation)) (VP (VBG combining) (NP (NNS HDACi) (NN EGFR) (JJ HER2-targeted) (NN therapy) (NN CRC) (NN treatment))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337|ES| 19:1 84:1 101:1 130:1 187:1 245:1 505:1 546:1 658:1 1042:1 1494:1 1495:1 1496:1 1497:1 1498:1 1499:1
-1 	|BT| (NP (NP (NN Overactivation) (NN Wnt-beta-catenin) (NN signaling)) (, ,) (PP (VBG including) (NP (NP (NN beta-catenin-TCF) (NN target) (NN gene) (NN expression)) (, ,) (NP (NP (NN hallmark) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 105:G02.149.115.800.925 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 35:1 115:1 160:1 195:1 245:1 561:1 1427:1 1500:1 1501:1 1502:1
-1 	|BT| (NP (NP (NN P53) (NN gene) (JJ deficient) (NN mouse)) (SBAR (-LRB- -LRB-) (S (S (NP (NN p53) (PRN (: -) (: /) (: -) (-RRB- -RRB-))) (VP (VBD found) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ malignant) (NN lymphoma) (NN hemangiosarcoma))))) (, ,) (IN whereas) (FRAG (NP (NN heterozygote)) (-LRB- -LRB-) (NP (NP (NP (NN p53)) (CC +) (: /) (: -) (-RRB- -RRB-) (NN mouse) (NN display) (JJ high) (NN incidence) (NN tumor) (JJ urinary) (NN bladder)) (VP (VBN treated) (NP (NN N-butyl-N) (: -) (-LRB- -LRB-) (NN 4-hydroxybutyl) (-RRB- -RRB-) (NN nitrosamine)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 157:G05.380.383 176:C04.557.386 434:E05.318.308.985.525.375 435:C04.557.450.795.390 436:C04.588.945.947.960 437:D02.654.442|ES| 2:1 7:1 9:1 10:1 14:1 19:1 37:1 52:1 178:1 372:1 564:1 591:1 648:1 802:1 1033:1 1099:1 1503:1 1504:1 1505:1 1506:1 1507:1 1508:1 1509:1 1510:1 1511:1 1512:1 1513:1 1514:1
-1 	|BT| (NP (NP (NN Pdcd4)) (S (-LRB- -LRB-) (NP (VBN programmed) (NP (NP (NN cell) (NN death) (CD 4) (-RRB- -RRB-) (NN gene)) (NN tumor) (NN suppressor) (NN expression))) (ADVP (RB frequently)) (VP (VBD down-regulated) (NP (NN tumor)) (, ,) (NP (NP (VBN considered) (JJ diagnostic) (JJ prognostic) (NN marker)) (NP (ADJP (RB well) (JJ promising)) (NN target) (JJ anti-cancer) (NN therapy)))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 52:E02 142:I01.880.604 158:D23.101 206:G05.360.340.024.340.375.249 263:E01 351:A17.360|ES| 2:1 7:1 9:1 10:1 14:1 19:1 94:1 115:1 130:1 160:1 319:1 411:1 534:1 698:1 700:1 787:1 884:1 903:1 1061:1 1112:1 1283:1 1515:1 1516:1 1517:1
-1 	|BT| (NP (NP (NP (NN Point) (NN mutation) (JJ K-ras) (NN gene)) (, ,) (VP (VBD found) (NP (NP (ADJP (QP (CD 10) (CD 30)) (NN %)) (NN lung) (NN adenocarcinoma)) (, ,) (NP (VBN regarded) (RB early) (NN event) (NN carcinogenesis)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 438:G05.365.590.675|ES| 2:1 9:1 19:1 34:1 37:1 205:1 207:1 255:1 328:1 369:1 1121:1 1128:1 1518:1 1519:1 1520:1 1521:1
-1 	|BT| (NP (NP (NP (JJ Primary) (JJ renal) (NN neoplasm) (NN ASPL-TFE3) (NN gene) (NN fusion) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (: :) (S (NP (JJ distinctive) (NN tumor) (NN entity)) (ADVP (RB previously)) (VP (VBD included) (PP (IN among) (NP (JJ renal) (NN cell) (NN carcinoma) (NN child))) (ADVP (JJ adolescent)))))) |ET| |BS|8:C04 274:C04.588.945.947.535 295:C04.557.470.200.025.390 359:G05.355.760.385 439:C04.557.450.590.775 440:M01.060.057 441:M01.060.406|ES| 7:1 9:1 19:1 94:1 104:1 304:1 451:1 922:1 935:1 936:1 1117:1 1287:1 1372:1 1522:1 1523:1 1524:1 1525:1 1526:1 1527:1 1528:1 1529:1 1530:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (VP (VBG Activating) (NP (NP (NP (NP (JJ somatic) (NN mutation) (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN gene)) (ADJP (ADJP (JJ present)) (ADJP (JJ small))) (NN subset) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 442:G05.360.340.024.340.375.500.791.295.300 443:G05.700.264|ES| 9:1 10:1 14:1 19:1 34:1 102:1 104:1 184:1 185:1 186:1 187:1 255:1 328:1 388:1 687:1 750:1 950:1 1285:1 1307:1
-1 	|BT| (S (NP (VBN Reduced) (NN ING1b) (NN gene) (NN expression)) (VP (VBP play) (NP (NP (JJ important) (NN role)) (NN carcinogenesis) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 50:M01.643 79:I03.450.642.693 110:C04.588.894.797.520.109.220.249 155:G05.355.310|ES| 9:1 18:1 19:1 31:1 94:1 115:1 120:1 207:1 238:1 328:1 694:1 902:1 1134:1 1531:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN EGFR) (NN gene) (NN mutation)) (VP (VBD identified) (NP (NP (CD 13) (NN %)) (NP (JJ primary) (NN tumor))))) |ET| |BS|8:C04 18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 7:1 9:1 19:1 34:1 104:1 187:1 344:1 369:1 623:1 710:1 1532:1
-1 	|BT| (S (NP (NN SMO)) (VP (MD might) (NP (NP (JJ good) (JJ therapeutic) (NN target) (NN patient)) (NP (JJ colorectal) (NN polyp) (NN carcinoma))) (, ,) (NP (RB even) (NN absence) (NN Hh) (NN signal) (NN activation)))) |ET| |BS|50:M01.643 52:E02 265:C04.557.470.200 444:C23.300.825|ES| 2:1 17:1 19:1 120:1 160:1 225:1 304:1 541:1 647:1 798:1 859:1 1268:1 1270:1 1318:1 1533:1 1534:1
-1 	|BT| (S (NP (NN SPOCK1) (NN act) (NN oncogene)) (VP (MD may) (NP (NP (JJ prognostic) (NN factor) (JJ therapeutic) (NN target) (NN patient)) (NP (NNP GBC))))) |ET| |BS|9:G05.360.340.024.340.375.500 50:M01.643 52:E02 81:E02.095.465.425.400.330.050.400|ES| 19:1 24:1 120:1 160:1 185:1 246:1 491:1 541:1 884:1 1535:1 1536:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN downregulation)) (VP (MD might) (VP (VBN involved) (SBAR (S (NP (NP (NN carcinogenesis)) (, ,) (NP (NN growth)) (, ,) (NP (NN invasion) (NN lung) (NN cancer))) (VP (MD could) (VP (VBN considered) (S (NP (JJ promising) (NN marker) (NN gauge) (NN aggressiveness) (NN lung) (NN cancer))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 45:G07.700.320.249 85:G02.111.087.225 158:D23.101 162:F01.145.126.125|ES| 2:1 18:1 19:1 102:1 207:1 328:1 534:1 595:1 620:1 774:1 793:1 798:1 908:1 925:1 1061:1 1316:1 1517:1 1537:1 1538:1 1539:1 1540:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBG finding) (SBAR (S (NP (JJ indicated) (NN PVT1/EZH2/LATS2) (NN interaction)) (VP (MD might) (VP (VB serve) (NP (JJ new) (NN target) (NN lung) (NN adenocarcinoma) (NN diagnosis) (NN therapy)))))))) |ET| |BS|52:E02 263:E01|ES| 2:1 19:1 130:1 160:1 255:1 328:1 532:1 618:1 712:1 798:1 927:1 1037:1 1537:1 1538:1 1541:1 1542:1
-1 	|BT| (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (JJ first) (NN time) (NN miR-372)) (VP (VBZ suppresses) (NP (NN tumorigenesis) (NN development) (NN EC))))))) (: ;) (FRAG (NP (NP (NN RhoC)) (JJ new) (ADJP (RB potentially) (JJ important)) (JJ therapeutic) (NN target)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 52:E02 322:G01.910|ES| 2:1 19:1 35:1 78:1 101:1 160:1 217:1 541:1 686:1 712:1 773:1 816:1 902:1 1081:1 1175:1 1537:1 1538:1 1543:1 1544:1 1545:1
-1 	|BT| (S (NP (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (JJ present) (NN work)) (VP (VBD revealed) (NP (JJ novel) (NN function) (NN TIP30)) (, ,) (VP (ADVP (RB possibly)) (VBN used) (S (NP (JJ independent) (ADJP (JJ prognostic) (NN factor) (JJ potential)) (JJ therapeutic) (NN target) (JJ gastric) (NN cancer)))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 445:I03.946|ES| 2:1 18:1 19:1 33:1 86:1 160:1 185:1 275:1 476:1 541:1 827:1 883:1 884:1 891:1 1307:1 1537:1 1538:1 1546:1 1547:1 1548:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN SRC-3)) (VP (MD may) (NP (JJ important) (NN oncogene) (JJ therapeutic) (NN target) (NN lung) (NN cancer))))))) |ET| |BS|9:G05.360.340.024.340.375.500 52:E02|ES| 2:1 18:1 19:1 24:1 160:1 328:1 491:1 541:1 793:1 796:1 902:1 1537:1 1538:1 1549:1
-1 	|BT| (S (NP (NNP TaqMan) (NN PCR) (NN genotyping) (NN technology)) (VP (VBD used) (VP (VB detect) (NP (NP (NP (NN genotype) (NN ITGA3) (NN gene) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN rs2230392)) (, ,) (NP (NN rs2285524) (NN rs16948627))) (-RRB- -RRB-))) (NP (JJ peripheral) (NN blood)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 61:E05.318.740.600.800 225:E05.337 386:F02.463.425.069 396:G05.380 434:E05.318.308.985.525.375 446:G05.365.795.598 447:C04.557.450.565.575.650 448:E05.393.620.500 449:A12.207.152 450:J01.897|ES| 2:1 7:1 9:1 10:1 14:1 19:1 171:1 336:1 476:1 780:1 875:1 1298:1 1329:1 1476:1 1511:1 1550:1 1551:1 1552:1 1553:1 1554:1 1555:1 1556:1 1557:1 1558:1 1559:1 1560:1 1561:1 1562:1
-1 	|BT| (S (NP (JJ Testis-specific) (NN Fank1) (NN gene) (JJ knockdown) (NN mouse)) (VP (VBP produce) (NP (NN oligospermia)) (PP (IN via) (NP (NN apoptosis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 400:E05.393.335.500 451:C12.294.365.700.508 452:A05.360.444.849|ES| 9:1 19:1 52:1 89:1 464:1 596:1 1563:1 1564:1 1565:1 1566:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (SBAR (IN whether) (S (S (VP (VBG combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam)))) (VP (MD could) (VP (VB offer) (NP (ADJP (ADJP (JJR better)) (ADJP (JJ therapeutic))) (NN effect) (NN combat) (NN HCC) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 74:1 75:1 130:1 131:1 221:1 441:1 541:1 691:1 904:1 908:1 1042:1 1088:1 1089:1 1498:1 1567:1 1568:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP evaluate) (NP (NN hypermethylation) (JJ spastic) (NN paraplegia-20) (NN promoter) (JJ potential) (NN biomarker) (JJ prognostic) (NN factor) (JJ gastric) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 158:D23.101 225:E05.337 453:C10.597.622.669|ES| 18:1 19:1 83:1 86:1 131:1 185:1 664:1 691:1 827:1 884:1 885:1 890:1 1567:1 1569:1 1570:1
-1 	|BT| (S (S (NP (DT The) (NN aim) (NN work)) (VP (VP (VB evaluate) (SBAR (IN whether) (S (NP (NN TP53) (NN mutation)) (VP (VBN classified) (ADVP (RB functionally)) (ADJP (JJ inactive)))))) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (JJR <)) (CC or) (ADJP (JJ =))) (ADJP (CD 20) (NN %)) (JJ wildtype) (NN transactivation) (NN ability)) (-RRB- -RRB-))) (S (NP (NP (JJ different) (JJ prognostic) (JJ predictive) (NN value) (NN CRC)) (VBN compared) (NN mutation)) (VP (VBD retained) (NP (JJ significant) (NN activity)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 385:F02.784.629.131 395:L01.100 445:I03.946 454:G05.355.315.800|ES| 10:1 14:1 19:1 34:1 50:1 135:1 221:1 245:1 312:1 369:1 399:1 414:1 533:1 691:1 884:1 890:1 1018:1 1248:1 1300:1 1546:1 1567:1 1571:1 1572:1 1573:1 1574:1 1575:1 1576:1 1577:1
-1 	|BT| (NP (NP (NP (DT The) (NN expression) (JJ gastric) (NN cancer) (NN marker) (NN MUC1)) (, ,) (NP (NN MUC2)) (, ,) (NP (NN MUC5AC)) (, ,) (NP (NN oncogene) (NN c-myc)) (, ,) (NP (NN c-met)) (, ,) (NP (NN cyclin) (NN E1)) (, ,) (NP (NN cancer) (NN stem) (NN cell) (NN marker) (NN CD44)) (VP (VBD determined) (NP (NN MGCC3I) (NN cell))))) |ET| |BS|41:A11 158:D23.101 332:A11.872.650|ES| 2:1 18:1 19:1 24:1 86:1 94:1 115:1 210:1 212:1 455:1 534:1 691:1 743:1 1106:1 1578:1 1579:1 1580:1 1581:1 1582:1 1583:1
-1 	|BT| (S (NP (NP (DT The) (NN lung) (NN adenocarcinoma) (NN cell) (NN bearing) (JJ K-ras) (NN gene) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN A549) (NN H820)) (-RRB- -RRB-))) (VP (VBD showed) (NP (ADJP (RB consistently) (JJR higher)) (NN level) (NN cell) (NN motility)) (S (PP (IN without) (NP (NP (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN TKB6) (NN TKB14)) (-RRB- -RRB-)))) (, ,) (NP (NN motility) (NN A549) (NN H820) (NN cell)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN dnAkt) (NN transfection)))))) |ET| |BS|18:G05.365.590 41:A11 122:C14.280.383 217:E05.393.350.810 455:B01.050.150.900.649.147.890|ES| 2:1 9:1 10:1 14:1 19:1 34:1 94:1 124:1 132:1 170:1 249:1 255:1 328:1 364:1 365:1 691:1 746:1 1121:1 1177:1 1195:1 1584:1 1585:1 1586:1 1587:1 1588:1 1589:1
-1 	|BT| (FRAG (NP (DT The) (NN morphology) (CD eight) (NN ASPL-TFE3) (JJ fusion-positive) (JJ renal) (NN tumor)) (, ,) (PP (IN although) (NP (NP (VBG overlapping) (NN aspect) (JJ classic) (NNS ASPS)) (, ,) (VP (ADVP (RB closely)) (VBZ resembles) (NP (NP (JJ renal) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN RCC)) (-RRB- -RRB-)))) (, ,) (NP (FW priori) (NN diagnosis) (NN case))))) |ET| |BS|263:E01 274:C04.588.945.947.535 295:C04.557.470.200.025.390|ES| 2:1 7:1 10:1 14:1 19:1 94:1 112:1 304:1 348:1 691:1 855:1 922:1 923:1 934:1 935:1 1037:1 1413:1 1590:1 1591:1 1592:1 1593:1 1594:1 1595:1 1596:1
-1 	|BT| (NP (NP (NP (DT The) (JJ recombinant) (NN plasmid)) (NP (VBN transfected) (JJ human) (ADJP (NN lung) (NN cancer) (NN A549) (NN cell) (JJ liposome-mediated)) (NN method)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 456:D25.479.517 457:G05.360.600|ES| 18:1 19:1 36:1 94:1 328:1 364:1 479:1 691:1 1420:1 1597:1 1598:1 1599:1
-1 	|BT| (S (NP (DT The) (JJ resultant) (NN MLL) (NN fusion) (NN protein)) (VP (VBN known) (VP (VBP mediate) (NP (NN leukaemia) (NN disruption) (JJ normal) (JJ epigenetic) (NN regulation) (NN target) (NN gene) (NN locus))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 142:I01.880.604 361:C04.557.337 458:G05.360.340.024.380|ES| 4:1 9:1 19:1 118:1 160:1 377:1 438:1 556:1 691:1 936:1 1207:1 1263:1 1600:1 1601:1 1602:1 1603:1
-1 	|BT| (S (NP (NP (DT The) (JJ significant) (NN association) (NN SNIP1) (NN c-Myc) (NN staining) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN tissue) (NN array) (NN evidence) (NN activity)) (VP (MD might) (VP (VBN linked)))) (VP (VBZ suggests) (SBAR (S (NP (NN SNIP1)) (VP (MD might) (NP (JJ important) (NN modulator) (NN c-Myc) (NN activity) (NN carcinogenesis))))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 98:A10 110:C04.588.894.797.520.109.220.249 386:F02.463.425.069|ES| 18:1 19:1 38:1 94:1 135:1 207:1 272:1 328:1 331:1 399:1 691:1 694:1 798:1 824:1 902:1 1298:1 1363:1 1604:1 1605:1 1606:1 1607:1
-1 	|BT| (S (NP (DT The) (JJ significant) (NN link) (NN tobacco) (NN loss) (NN p16) (NN locus)) (VP (VBZ identifies) (NP (JJ additional) (JJ genetic) (NN target) (NN smoking) (NN pathogenesis) (NN lung) (NN cancer)))) |ET| |BS|203:G05.360.340.024.340.375.249.375 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 461:F01.145.958.500 462:J01.637.836|ES| 18:1 19:1 32:1 135:1 160:1 328:1 377:1 501:1 691:1 864:1 980:1 1313:1 1608:1 1609:1 1610:1 1611:1
-1 	|BT| (S (NP (DT The) (JJ siRNA-mediated) (NN DEPDC1) (NN depletion)) (VP (VBD resulted) (NP (NP (JJ significant) (NN inhibition) (NN proliferation) (NN delay) (NN cell) (NN cycle) (NN progression) (NN NPC) (NN cell) (NN line)) (, ,) (NP (NN CNE-1) (NN HNE-1))))) |ET| |BS|16:C23.550.291.656 43:F01.145.544 117:D13.150.650.700 353:G04.299.134|ES| 2:1 19:1 48:1 94:1 103:1 135:1 136:1 264:1 299:1 594:1 601:1 691:1 1174:1 1612:1 1613:1 1614:1 1615:1 1616:1
-1 	|BT| (NP (NP (DT The) (JJ unbalanced) (NN translocation)) (, ,) (NP (NN der) (-LRB- -LRB-) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;) (CD q25)) (-RRB- -RRB-) (, ,) (NP (NP (JJ characteristic) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (PRN (-LRB- -LRB-) (NP (NN ASPS)) (-RRB- -RRB-)))) |ET| |BS|439:C04.557.450.590.775 463:C23.550.210.870|ES| 2:1 10:1 14:1 19:1 217:1 336:1 451:1 691:1 923:1 929:1 930:1 931:1 932:1 1117:1 1287:1 1524:1 1617:1 1618:1 1619:1
-1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
-1 	|BT| (S (NP (DT These) (NNS data) (NN challenge) (NN view) (NN MYH11) (NN passive) (NN differentiation) (NN marker)) (VP (VBG functioning) (S (NP (NN muscle) (NN contraction)) (VP (VBP add) (S (VP (VBG understanding) (NP (JJ intestinal) (NN neoplasia)))))))) |ET| |BS|74:G04.299.151 102:C04.588.274.476.411 158:D23.101 239:F02.463.188.357 375:Z01.639.100 464:G11.427.590.540|ES| 19:1 109:1 215:1 534:1 640:1 792:1 793:1 905:1 1371:1 1626:1 1627:1 1628:1 1629:1 1630:1 1631:1 1632:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
-1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP indicate) (SBAR (S (NP (NNP BIM) (NN deletion) (NN polymorphism) (JJ common) (JJ Korean) (NN NSCLC) (NN patient)) (ADVP (RB significantly)) (VP (VBP affect) (NP (JJ intrinsic) (JJ biologic) (NN function) (JJ BH3-only) (NN protein)))))))) |ET| |BS|7:D12.776 50:M01.643 110:C04.588.894.797.520.109.220.249 306:G05.355.600.800 307:G05.365.795 433:F01.470.047 465:D23|ES| 4:1 19:1 33:1 120:1 124:1 329:1 655:1 792:1 927:1 1059:1 1060:1 1479:1 1486:1 1633:1 1634:1 1635:1 1636:1 1637:1
-1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
-1 	|BT| (NP (NP (DT These) (UCP (S (VP (VBG finding) (PP (VBN suggested) (NP (NN endostatin) (NN gene) (NN therapy))) (, ,) (S (VP (VBG using) (NP (JJ cationic) (JJ vector-mediated) (JJ intravenous) (NN gene) (NN transfer)))))) (, ,) (MD might) (NP (NP (JJ feasible) (NN strategy) (JJ organ-targeted) (NN prevention) (NN regulation)) (JJ possible) (VBN disseminated) (NN cancer))))) |ET| |BS|123:G05.360.337 142:I01.880.604 466:D12.644.276.100.450.750 467:D01.248.497.300|ES| 2:1 9:1 18:1 19:1 130:1 350:1 438:1 792:1 798:1 925:1 927:1 1114:1 1359:1 1474:1 1640:1 1641:1 1642:1 1643:1 1644:1 1645:1 1646:1 1647:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NP (NN favour) (ADJP (ADJP (JJ non-invasive)) (, ,) (ADJP (JJ ALK-gene))) (NN status)) (JJ pre-screening) (JJ routine) (NN basis) (NNS CTCs)) (VP (VBN isolated) (NP (NP (NN patient) (NN lung) (NN cancer)) (SBAR (S (NP (JJ open) (JJ new) (NN avenue) (JJ real-time) (NN monitoring)) (VP (VBD adapted) (NP (VBN targeted) (NN therapy)))))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 52:E02 322:G01.910 468:G07.700.062.133|ES| 2:1 16:1 18:1 19:1 101:1 120:1 130:1 328:1 416:1 712:1 792:1 874:1 1140:1 1361:1 1648:1 1649:1 1650:1 1651:1 1652:1 1653:1 1654:1 1655:1 1656:1 1657:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP implicate) (S (NP (NN SPARC) (NN promoter) (NN methylation) (JJ important) (NN factor) (NN tumorigenesis) (JJ gastric) (NN carcinoma)) (VP (VB provide) (NP (NP (JJ new) (NN insight) (JJ potential) (NN use)) (NP (NNP SPARC) (JJ novel) (NN biomarker) (JJ potential) (JJ clinical) (NN importance) (JJ human) (JJ gastric) (NN cancer)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 36:G02.111.087.029.538 37:D12.776.157.125.715 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875 158:D23.101 259:D12.776.395.240.150.500 265:C04.557.470.200|ES| 18:1 19:1 36:1 78:1 81:1 82:1 83:1 84:1 86:1 101:1 185:1 304:1 711:1 712:1 792:1 827:1 885:1 891:1 902:1 1141:1 1658:1 1659:1 1660:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ VES-induced) (NN expression) (NN NAG-1) (NN mRNA/protein)) (VP (VBN regulated) (NP (JJ transcriptional/post-transcriptional) (NN mechanism) (NN p38) (JJ kinase-dependent) (NN manner) (NN NAG-1) (JJ chemopreventive/therapeutic) (NN target) (NN prostate) (NN cancer)))))))) |ET| |BS|7:D12.776 52:E02 111:D13.444.735.544 142:I01.880.604 209:G02.111.087.847 469:D08.811.913.696 470:C02.782.160.927|ES| 18:1 19:1 77:1 101:1 115:1 160:1 162:1 792:1 1479:1 1661:1 1662:1 1663:1 1664:1 1665:1 1666:1 1667:1 1668:1 1669:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP reveal) (NP (NN association) (NN SNP) (NN rs7646) (NN NTD) (NN risk))) (VP (VBZ involves) (NP (NP (NN difference) (NN microRNA) (NN regulation)) (, ,) (NP (NN highlight) (NN importance) (JJ genotype-dependent) (JJ differential) (NN microRNA) (NN regulation) (NN relation) (JJ human) (NN disease) (NN risk)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 61:E05.318.740.600.800 142:I01.880.604 184:D13.150.650.319 288:C23.550.288 386:F02.463.425.069 396:G05.380 411:C10.500.680 446:G05.365.795.598|ES| 2:1 19:1 36:1 101:1 171:1 438:1 792:1 857:1 998:1 1298:1 1561:1 1660:1 1670:1 1671:1 1672:1 1673:1 1674:1 1675:1 1676:1 1677:1 1678:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NN ERBB4) (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN target) (NN subset) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 259:D12.776.395.240.150.500|ES| 19:1 101:1 160:1 245:1 541:1 792:1 796:1 891:1 1285:1 1679:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NP (NN IFN-alpha) (NN gene) (NN therapy) (JJ promising) (NN strategy) (NN treat) (NNP HCC) (NN patient)) (JJ concomitant) (NN liver) (NN cirrhosis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 104:C04.557.470.200.025.255 357:C06.552.630|ES| 9:1 19:1 101:1 120:1 130:1 441:1 792:1 796:1 836:1 1090:1 1114:1 1199:1 1517:1 1680:1 1681:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (VBN suggested) (NN PSMA6) (NN serf) (JJ attractive) (NN target) (JJ high) (JJ therapeutic) (NN index) (NN lung) (NN cancer)))) |ET| |BS|52:E02|ES| 18:1 19:1 101:1 160:1 178:1 328:1 541:1 721:1 792:1 882:1 925:1 1242:1 1682:1
-1 	|BT| (S (NP (NP (DT This) (NN study)) (VP (VBN designed))) (VP (VBP identify) (SBAR (S (NP (JJ TLR4-mediated) (NN gene) (NN expression) (NN pathway)) (VP (MD may) (VP (VBN used) (SBAR (S (NP (JJ prognostic) (NP (NN indicator) (NN susceptibility) (NN lung) (NN tumorigenesis) (NN mouse))) (VP (VBP provide) (NP (NN insight) (NN mechanism))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 155:G05.355.310 182:A04.411 401:C23.550.291.687 471:D27.720.470.410|ES| 9:1 19:1 52:1 78:1 115:1 131:1 162:1 328:1 383:1 476:1 491:1 711:1 807:1 832:1 884:1 1141:1 1353:1 1683:1 1684:1 1685:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
-1 	|BT| (S (NP (DT This)) (VP (VBZ suggests) (SBAR (S (NP (NN c-Jun) (NN inhibition)) (VP (MD may) (VP (VB serve) (NP (JJ therapeutic) (NN target) (NN liver) (NN cancer)))))))) |ET| |BS|43:F01.145.544 52:E02|ES| 18:1 19:1 103:1 160:1 331:1 491:1 532:1 541:1 807:1 836:1 1686:1
-1 	|BT| (S (PP (IN Through) (NP (NN combination) (NNS data) (NN mining) (JJ biochemical) (NN assay))) (, ,) (VP (VBD identified) (NP (NP (NN trophinin)) (, ,) (VP (MD could) (VP (VB enhance) (NP (NP (NN cell) (NN invasion)) (, ,) (NP (NP (JJ novel) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer)))))))) |ET| |BS|41:A11 106:E05.091 182:A04.411 259:D12.776.395.240.150.500 472:L01.313.500.750.280.199 473:E01.789.625|ES| 2:1 18:1 19:1 94:1 185:1 310:1 328:1 530:1 620:1 623:1 793:1 884:1 891:1 908:1 1128:1 1129:1 1266:1 1687:1 1688:1 1689:1 1690:1
-1 	|BT| (NP (NP (ADVP (RB Thus)) (, ,) (NP (NP (NN inactivation) (NN p16) (NN gene) (JJ common) (NN event) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (NP (NN mechanism) (NN gene) (NN alteration)) (VP (VBZ differs) (NP (NN smoker) (NN nonsmoker)))))) |ET| |BS|18:G05.365.590 42:G05.355.315.203.374 110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375|ES| 2:1 9:1 18:1 19:1 94:1 162:1 205:1 328:1 655:1 694:1 951:1 1313:1 1314:1 1315:1 1691:1 1692:1 1693:1
-1 	|BT| (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NN DAP) (NN kinase) (NN promoter)) (NN methylation)) (VP (VBZ contributes) (NP (NP (NN TRAIL) (NN resistance) (NN NSCLC) (NN cell)) (, ,) (NP (NP (VBN measured) (NN DAP) (NN kinase) (NN promoter) (NN methylation) (NN gene) (NN expression) (NN status)) (NP (CD 11) (NN NSCLC) (NN cell) (NN line)))))))))) (VP (VBD correlated) (NP (NN methylation/expression) (NN status) (NN sensitivity) (NN cell) (NN TRAIL)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 94:A11.251.210 110:C04.588.894.797.520.109.220.249 155:G05.355.310 228:E05.978 474:D08.811.913.696.620.682.700.125.387|ES| 2:1 9:1 19:1 74:1 81:1 83:1 94:1 115:1 221:1 264:1 329:1 416:1 446:1 470:1 607:1 789:1 828:1 845:1 1057:1 1094:1 1694:1 1695:1 1696:1
-1 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (JJ pathogenic) (NN role) (NN MLL) (NN fusion) (NN protein) (NN HOX) (NN dysregulation) (NN leukaemia))))) (, ,) (VP (VBD generated) (NP (JJ novel) (JJ haematopoietic) (JJ lineage-specific) (NN Mll-Een) (NN knock-in) (NN mouse) (NN model)) (S (VP (VBG using) (NP (JJ Cre-mediated) (NN inversion) (NN strategy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 259:D12.776.395.240.150.500 327:G06.930 361:C04.557.337 475:C23.550.210.190 476:A15.378|ES| 2:1 4:1 19:1 31:1 52:1 72:1 73:1 350:1 828:1 891:1 936:1 1114:1 1202:1 1204:1 1207:1 1263:1 1697:1 1698:1 1699:1 1700:1 1701:1 1702:1 1703:1 1704:1
-1 	|BT| (SINV (S (VP (TO To) (VP (VB determine) (NP (NP (JJ genetic) (JJ molecular) (JJ characteristic) (NN tumor)) (VP (VBG carrying) (NP (NN EGFR) (NN gene) (NN mutation))))))) (, ,) (VBD investigated) (S (S (NP (NN EGFR) (NN gene) (NN status) (NN lung) (NN adenocarcinoma)) (VP (VBD evaluated) (NP (NN association) (JJ specific) (JJ characteristic) (NN patient) (NN tumor)))) (, ,) (NP (NP (NP (NP (NX (NN mutation) (NNP KRAS) (NN p53)) (, ,) (NN EGFR) (NN ErbB2) (NN gene) (NN amplification)) (, ,) (NP (NN level) (NN EGFR) (NN HER2) (NN protein)) (, ,)) (NN level) (JJ downstream) (NN effector) (NN EGFR)) (, ,) (NP (JJ phospho-extracellular) (JJ signal-regulated) (NN kinase) (NN phospho-S6) (NN protein))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 8:C04 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337 247:G01.374.676.530 358:G05.360.340.024.340.375.500.791.295.300 386:F02.463.425.069 388:G05.360.340.024.340.375.500.791.550 392:G05.355.315.250 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 7:1 9:1 12:1 19:1 34:1 74:1 120:1 161:1 187:1 188:1 249:1 255:1 328:1 336:1 403:1 416:1 470:1 540:1 560:1 570:1 780:1 828:1 850:1 864:1 921:1 1298:1 1305:1 1705:1 1706:1 1707:1 1708:1
-1 	|BT| (S (NP (PP (TO To) (NP (NN knowledge))) (, ,) (JJ first) (NN study) (NN report) (NN change) (NN lncRNA) (NN expression) (NN profile)) (VP (VBD induced) (NP (NN resveratrol) (NN lung) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 479:G08.686.157.500 480:D13.444.735.790.375 481:D13.444.735.790.375 482:K01.468|ES| 2:1 18:1 19:1 115:1 131:1 200:1 328:1 412:1 417:1 816:1 828:1 1709:1 1710:1 1711:1 1712:1
-1 	|BT| (NP (NP (JJ Tubular) (NN atrophy) (JJ low) (NN netrin-1) (NN gene) (NN expression)) (NP (VBN associated) (VBN delayed) (NN kidney) (NN allograft) (NN function))) |ET| |BS|155:G05.355.310 483:C23.300.070 484:A01.941.500 485:A05.810.453 486:E04.936.864|ES| 9:1 19:1 33:1 115:1 169:1 531:1 1713:1 1714:1 1715:1 1716:1 1717:1 1718:1
-1 	|BT| (S (S (VP (VBG Using) (NP (NP (JJ Mll-Een-expressing) (JJ leukaemic) (NN cell) (NN line)) (VP (VBN derived) (S (NP (NP (NN bone) (NN marrow) (NN Mll) (-LRB- -LRB-) (NN Een) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (VP (JJ mutant) (NP (NN mouse)))))))) (, ,) (VP (VBD showed) (NP (NP (NN induction) (NN Hox) (NN gene) (JJ leukaemic) (NN cell)) (VP (VBN associated) (NP (NP (JJ hypomethylated) (NN promoter) (NN region)) (NP (JJ aberrant) (JJ active) (NN chromatin) (NN state) (NN Hox) (NN locus))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 41:A11 94:A11.251.210 196:G02.111.570.080.689.675 397:A11.284.430.106.279.345.190.160.180 487:G05.355.315.800 488:A15.382.216|ES| 2:1 9:1 10:1 14:1 19:1 52:1 83:1 94:1 132:1 169:1 197:1 264:1 377:1 526:1 667:1 736:1 811:1 1203:1 1286:1 1346:1 1347:1 1348:1 1719:1 1720:1 1721:1 1722:1 1723:1 1724:1 1725:1 1726:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBP demonstrate) (SBAR (S (NP (NN dysregulation) (NN HAO2) (JJ early) (NN event) (NN development) (NN HCC)) (VP (MD may) (VP (VB represent) (NP (ADJP (ADJP (JJ useful)) (ADJP (JJ diagnostic))) (JJ prognostic) (NN marker) (JJ human) (NN HCC)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 158:D23.101 263:E01|ES| 5:1 19:1 35:1 36:1 205:1 441:1 491:1 502:1 534:1 799:1 843:1 884:1 903:1 1036:1 1128:1 1202:1 1727:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (NP (NP (JJ allelic) (NN loss) (NNS metaplasias)) (NP (JJ bronchiolar) (NN epithelium) (NN IPF) (NN FISH) (NN analysis) (NN FHIT) (NN gene))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 48:C23.550.589 62:A10.272 260:E01.370.225.562 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500 489:B01.050.150.900.493|ES| 9:1 19:1 32:1 173:1 661:1 843:1 938:1 946:1 1122:1 1222:1 1223:1 1475:1 1728:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (S (NP (JJ balanced) (NN nature)) (-LRB- -LRB-) (NP (NP (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation) (NN fluorescence) (FW situ) (NN hybridization)) (NP (CD seven) (JJ renal) (NN tumor)) (ADVP (RB thus)) (VP (VBN analyzed))) (, ,) (NP (NP (NN contrast)) (ADJP (RB sharply) (JJ unbalanced)) (NN nature) (NN translocation) (NNS ASPS))))))) |ET| |BS|274:C04.588.945.947.535 463:C23.550.210.870 490:E01.370.225.500.620.670.325.350 491:D27.505.259.500 492:K01.637|ES| 2:1 7:1 10:1 14:1 19:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 938:1 1168:1 1334:1 1392:1 1617:1 1618:1 1729:1 1730:1 1731:1 1732:1 1733:1 1734:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP describe) (ADVP (RB herein)) (SBAR (S (NP (NP (CD eight) (RB morphologically) (JJ distinctive) (JJ renal) (NN tumor)) (VP (VBG occurring) (NP (JJ young) (NNS people)))) (VP (VBP bear) (NP (NP (JJ identical) (NN ASPL-TFE3) (NN fusion) (NN transcript) (NN ASPS)) (, ,) (FRAG (NP (NN distinction)) (-LRB- -LRB-) (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation)) (ADJP (RB cytogenetically) (JJ balanced)) (JJ renal) (NN tumor))))))))) |ET| |BS|274:C04.588.945.947.535 455:B01.050.150.900.649.147.890 463:C23.550.210.870 493:M01|ES| 2:1 7:1 10:1 14:1 19:1 111:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 935:1 936:1 937:1 1525:1 1590:1 1618:1 1735:1 1736:1 1737:1 1738:1 1739:1 1740:1 1741:1 1742:1 1743:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (NP (JJ potential) (NN TFPI2) (NN biomarker) (JJ early) (NN detection) (NN CRC)) (VP (VBG using) (NP (NP (NN stool) (JJ DNA-based) (NN assay) (NN patient)) (JJ nonmetastatic) (NN CRC) (JJ average-risk) (NN noncancer) (NN control) (NN candidate) (NN screening)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 61:E05.318.740.600.800 106:E05.091 158:D23.101 198:D13.444.308 333:D01.045 355:A12.459 375:Z01.639.100 494:E01.390|ES| 19:1 120:1 245:1 289:1 310:1 350:1 499:1 827:1 843:1 885:1 1023:1 1128:1 1184:1 1185:1 1188:1 1243:1 1744:1 1745:1 1746:1 1747:1
-1 	|BT| (S (NP (PRP We)) (VP (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN kallistatin) (NN gene) (NN therapy)) (VP (VBD suppressed) (NP (NP (NN growth) (NN HCC) (NN tumor) (JJ anti-angiogenic) (NN activity)) (, ,) (NP (NN meloxicam)) (, ,) (NP (JJ selective) (NN COX-2) (NN inhibitor))))))) (, ,) (VP (VBD inhibited) (NP (NN proliferation) (JJ induced) (NN apoptosis) (JJ human) (NN HCC) (NN cell) (NN vitro))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 349:D27.505.519.389.310.500|ES| 2:1 7:1 9:1 19:1 36:1 76:1 89:1 94:1 102:1 130:1 216:1 299:1 307:1 365:1 380:1 399:1 412:1 441:1 843:1 993:1 1088:1 1089:1 1527:1 1748:1 1749:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (NNP BIM) (NN intron) (CD 2) (NN deletion) (NN polymorphism) (NN increase) (NN lung) (NN cancer) (NN risk)) (VP (VBZ predicts) (NP (NP (NP (JJ poor) (NN prognosis) (JJ non-small) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN patient))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 159:I01.880.735.634 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 10:1 14:1 18:1 19:1 40:1 120:1 148:1 171:1 328:1 329:1 544:1 545:1 694:1 843:1 1058:1 1059:1 1060:1 1633:1 1750:1 1751:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NP (NP (NP (JJ multiple) (JJ somatic) (NN mutation) (NN CCPRCC) (NN case)) (, ,) (PP (VBG including) (ADJP (JJ recurrent)))) (PRN (-LRB- -LSB-) (NP (NP (CD 3/14) (NN case)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN %)) (-RRB- -RRB-))) (-RRB- -RSB-))) (JJ non-synonymous) (NN T992I) (NN mutation) (NN MET) (NN proto-oncogene)) (, ,) (NP (NP (NN gene)) (VP (VBN associated) (NP (NP (JJ epithelial-to-mesenchymal) (NN transition)) (PRN (-LRB- -LRB-) (NP (NN EMT)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 235:G05.360.340.024.340.375.500.791 443:G05.700.264 495:G04.299.335.500 496:C23.550.291.937 497:G05.365.590.650|ES| 2:1 9:1 10:1 14:1 19:1 34:1 169:1 369:1 388:1 552:1 561:1 563:1 623:1 649:1 843:1 934:1 957:1 1373:1 1378:1 1752:1 1753:1 1754:1 1755:1 1756:1 1757:1 1758:1 1759:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
-1 	|BT| (NP (NP (NP (NP (NN Xeroderma) (NN pigmentosum) (NN variant)) (PRN (-LRB- -LRB-) (NP (NN XP-V)) (-RRB- -RRB-))) (NP (JJ rare) (JJ genetic) (NN disease)) (, ,) (NP (VBN characterized) (NN sunlight) (NN sensitivity) (NN predisposition) (JJ cutaneous) (NN malignancy)))) |ET| |BS|401:C23.550.291.687 499:G01.358.500.505.650.836 500:C23.550.291.906 501:C04.834.867 502:C16.320|ES| 2:1 10:1 14:1 19:1 49:1 607:1 864:1 985:1 990:1 998:1 1322:1 1764:1 1765:1 1766:1 1767:1 1768:1 1769:1
1 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VBZ indicates) (SBAR (S (NP (NNS AR)) (VP (VBZ upregulates) (NP (NP (NN expression) (NN tumor) (NN suppressor) (NN gene) (NN PTEN) (NN promoter)) (NN activation) (NN breast) (NN cancer))))))) |ET| |BS|155:G05.355.310 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 18:1 19:1 23:1 83:1 115:1 131:1 225:1 628:1 658:1 659:1 700:1 1936:1 2152:1 2153:1
1 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBP identify) (NP (NP (NN network) (NN protein)) (, ,) (PP (VBG including) (NP (NP (NP (NN osteopontin)) (PRN (-LRB- -LRB-) (NP (NN OPN)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Matrix) (NN metalloproteinase-9)) (PRN (-LRB- -LRB-) (NP (NN MMP-9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Met) (NN complement) (NN factor) (NN H)) (PRN (-LRB- -LRB-) (NP (NN CFH)) (-RRB- -RRB-))) (, ,) (VP (ADVP (RB directly)) (VBN regulated) (NP (NP (NN LSF) (NN play) (JJ important) (NN role)) (JJ LSF-induced) (NN hepatocarcinogenesis)))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 112:D12.776.097.820 142:I01.880.604 350:D12.644.276.374.625 586:D08.811.277.656.300.480.205.360 587:D12.776.124.486.274.920.325.200 588:I01.880.853.500.600|ES| 2:1 4:1 10:1 14:1 19:1 31:1 131:1 185:1 238:1 561:1 612:1 621:1 658:1 832:1 900:1 902:1 1160:1 1664:1 2150:1 2154:1 2155:1 2156:1 2157:1 2158:1 2159:1 2160:1 2161:1 2162:1
1 	|BT| (S (NP (NN Overexpression) (NN miR-375) (NN liver) (NN cancer) (NN cell)) (VP (VBD decreased) (NP (NP (NN cell) (NN proliferation)) (, ,) (NP (NN clonogenicity)) (, ,) (NP (NN migration/invasion))) (ADVP (RB also)) (VP (VBD induced) (NP (NN G1) (NN arrest) (NN apoptosis))))) |ET| |BS|39:G04.299.139.160 41:A11 183:G04.299.233.750 262:A11.436.348|ES| 2:1 5:1 18:1 19:1 89:1 94:1 202:1 299:1 412:1 602:1 668:1 669:1 670:1 836:1 1975:1 2163:1
1 	|BT| (S (NP (NN p53)) (VP (VBZ promotes) (NP (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)) (VP (VBG inducing) (NP (NN HMGB1) (NN release)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 525:C23.550.470 585:D12.644.276.087.371 589:E02.204.125|ES| 12:1 19:1 298:1 900:1 1849:1 1864:1 2164:1 2165:1
